SG11201903846TA - 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) - Google Patents

9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Info

Publication number
SG11201903846TA
SG11201903846TA SG11201903846TA SG11201903846TA SG11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA
Authority
SG
Singapore
Prior art keywords
international
cabp
english
applicant
bacterial pneumonia
Prior art date
Application number
SG11201903846TA
Other languages
English (en)
Inventor
Evangelos L Tzanis
Paul Mcgovern
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of SG11201903846TA publication Critical patent/SG11201903846TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201903846TA 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) SG11201903846TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662416010P 2016-11-01 2016-11-01
US201662422843P 2016-11-16 2016-11-16
US201762480516P 2017-04-02 2017-04-02
US201762500611P 2017-05-03 2017-05-03
US201762514415P 2017-06-02 2017-06-02
PCT/US2017/059165 WO2018085216A1 (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquire bacterial pneumonia (cabp)

Publications (1)

Publication Number Publication Date
SG11201903846TA true SG11201903846TA (en) 2019-05-30

Family

ID=62076212

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903846TA SG11201903846TA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
SG10201913599RA SG10201913599RA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913599RA SG10201913599RA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Country Status (14)

Country Link
US (4) US10383884B2 (enrdf_load_stackoverflow)
EP (1) EP3534908B1 (enrdf_load_stackoverflow)
JP (3) JP7545803B2 (enrdf_load_stackoverflow)
CN (1) CN110087655A (enrdf_load_stackoverflow)
AU (1) AU2017353588B2 (enrdf_load_stackoverflow)
BR (1) BR112019008897A2 (enrdf_load_stackoverflow)
CA (1) CA3042514A1 (enrdf_load_stackoverflow)
MX (2) MX2019005070A (enrdf_load_stackoverflow)
MY (1) MY200446A (enrdf_load_stackoverflow)
PH (1) PH12019500960A1 (enrdf_load_stackoverflow)
RU (1) RU2019113715A (enrdf_load_stackoverflow)
SG (2) SG11201903846TA (enrdf_load_stackoverflow)
TW (3) TW201821082A (enrdf_load_stackoverflow)
WO (1) WO2018085216A1 (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903846TA (en) * 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (enrdf_load_stackoverflow) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
CA999855A (en) 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US5064821A (en) 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US5589470A (en) 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US4806529A (en) 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US4806372A (en) 1985-02-15 1989-02-21 Georgia Oil & Gas Co., Inc. Nitrite-free-curing of bacon and product thereof
US6756365B2 (en) 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
IL137445A0 (en) 1998-01-23 2001-07-24 Tufts College Pharmaceutically active compounds and methods of use thereof
US6256365B1 (en) 1999-08-16 2001-07-03 Analogic Corporation Apparatus and method for reconstruction of images in a computed tomography system using oblique slices
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6849615B2 (en) 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
PT1240133E (pt) 1999-09-14 2006-07-31 Tufts College Processos para preparar tetraciclinas substituidas com quimicas baseadas em metais de transicao
AU3105801A (en) 2000-01-24 2001-07-31 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
BR0109725A (pt) 2000-03-31 2003-02-04 Tufts College Composto de tetraciclina substituìdo, método para tratar um estado responsivo a tetraciclina em um mamìfero, composição farmacêutica, método para sintetizar um composto de tetraciclina 7- ou 9-substituìdo, e, intermediário reativo
AU2001259701A1 (en) 2000-05-15 2001-11-26 Paratek Pharmaceuticals, Inc 7-substituted fused ring tetracycline compounds
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20040224927A1 (en) 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
WO2001098236A2 (en) 2000-06-16 2001-12-27 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
CZ303702B6 (cs) 2000-07-07 2013-03-20 Trustees Of Tufts College Minocyklinové slouceniny
JP5044084B2 (ja) 2000-07-07 2012-10-10 トラスティーズ・オブ・タフツ・カレッジ ７−置換テトラサイクリン化合物
EP2166000A1 (en) 2000-07-07 2010-03-24 Trustees Of Tufts College 7-, 8- and 9-substituted tetracycline compounds
US20050143353A1 (en) 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
EP1241160A1 (en) 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
DE60135387D1 (de) 2001-03-13 2008-09-25 Paratek Pharm Innc 7,9 substituierte tetracyclinverbindungen
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
WO2002072506A2 (en) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
JP2004530661A (ja) 2001-03-14 2004-10-07 パラテック ファーマシューティカルズ インコーポレイテッド 抗真菌剤としての置換テトラサイクリン化合物
EP1381372A2 (en) 2001-03-14 2004-01-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
WO2003055441A2 (en) 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
US20030069721A1 (en) 2001-09-10 2003-04-10 Paratek Pharmaceuticals, Inc. Computational method for determining oral bioavailability
EP2311799A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
KR101014918B1 (ko) 2002-03-08 2011-02-15 파라테크 파마슈티컬스, 인크. 아미노-메틸 치환된 테트라시클린 화합물
CN1653037A (zh) 2002-03-21 2005-08-10 帕拉特克药品公司 取代的四环素化合物
JP4416652B2 (ja) 2002-07-12 2010-02-17 パラテック ファーマシューティカルズ インコーポレイテッド ３、１０、および１２ａ置換されたテトラサイクリン化合物
WO2004038000A2 (en) 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060287283A1 (en) 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
EP2295404A3 (en) 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2332904A3 (en) 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
US8466132B2 (en) 2004-10-25 2013-06-18 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2006047671A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
US8088755B2 (en) 2005-02-04 2012-01-03 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
EP1910273A2 (en) 2005-07-21 2008-04-16 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US9078811B2 (en) 2006-01-24 2015-07-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
CA2652346A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
DK2120963T3 (en) 2006-12-21 2019-01-14 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
MX2009006846A (es) 2006-12-21 2009-08-20 Paratek Pharm Innc Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
JP2010525069A (ja) 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
CN101784517A (zh) 2007-07-06 2010-07-21 帕拉特克药品公司 合成取代的四环素化合物的方法
KR20100126469A (ko) * 2008-03-05 2010-12-01 파라테크 파마슈티컬스, 인크. 미노사이클린 화합물 및 이들의 사용 방법
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
AU2009236631A1 (en) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
TW202021946A (zh) 2008-05-19 2020-06-16 美商派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
SG10201806714PA (en) 2008-08-08 2018-09-27 Tetraphase Pharmaceuticals Inc C7-fluoro substituted tetracycline compounds
KR102656263B1 (ko) 2015-03-24 2024-04-09 파라테크 파마슈티컬스, 인크. 생물방어를 위한 미노시클린 화합물
CN109152789A (zh) * 2016-03-24 2019-01-04 帕拉特克药品公司 用于治疗和预防艰难梭菌感染的方法
CN109414445A (zh) 2016-05-02 2019-03-01 帕拉特克药品公司 9-氨基甲基米诺环素化合物及其在泌尿道感染(uti)治疗中的应用方法
TW202206081A (zh) 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
SG11201903846TA (en) * 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Also Published As

Publication number Publication date
TW202506134A (zh) 2025-02-16
CA3042514A1 (en) 2018-05-11
TW202423450A (zh) 2024-06-16
SG10201913599RA (en) 2020-02-27
AU2017353588A1 (en) 2019-06-20
JP2019532976A (ja) 2019-11-14
JP2025041746A (ja) 2025-03-26
US10383884B2 (en) 2019-08-20
TW201821082A (zh) 2018-06-16
EP3534908B1 (en) 2025-07-09
US20180153908A1 (en) 2018-06-07
WO2018085216A1 (en) 2018-05-11
EP3534908A4 (en) 2020-05-27
MY200446A (en) 2023-12-26
US10835542B2 (en) 2020-11-17
RU2019113715A3 (enrdf_load_stackoverflow) 2020-12-07
AU2017353588B2 (en) 2022-07-14
MX2023004966A (es) 2023-05-24
JP2023058513A (ja) 2023-04-25
CN110087655A (zh) 2019-08-02
PH12019500960A1 (en) 2019-08-19
US20210052609A1 (en) 2021-02-25
RU2019113715A (ru) 2020-12-03
JP7545803B2 (ja) 2024-09-05
BR112019008897A2 (pt) 2019-08-13
US20200009162A1 (en) 2020-01-09
MX2019005070A (es) 2019-09-23
EP3534908A1 (en) 2019-09-11
US20250186465A1 (en) 2025-06-12
WO2018085216A8 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201809751XA (en) Egfr inhibitor compounds
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201909722WA (en) Methods and systems for high-throughput blood component collection
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201908326YA (en) Methods of treating neurodegenerative diseases